Thursday, April 5, 2018

Genprex Closes IPO

Austin-based Genprex, a company developing gene therapies for treating non-small cell lung cancer, has closed its IPO, saying it sold an aggregate of 1,280,000 shares of common stock at a public offering price of $5.00 per share. The IPO raised $6.4M for the company. Genprex now trades on the NASDAQ as GNPX. Genprex's IPO was underwritten by Network 1 Financial Securities.